Related Experiment Video
Updated: Jun 10, 2025
08:22
Electrowetting-based Digital Microfluidics Platform for Automated Enzyme-linked Immunosorbent Assay
Published on: February 23, 2020
9.5K
Electrode Droplet Microarray (eDMA): An Impedance Platform for Label-Free Parallel Monitoring of Cellular Drug
Meijun Zhou1, Joaquin E Urrutia Gomez1,2, Nikolaj K Mandsberg1
1Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.
Advanced Healthcare Materials
|October 15, 2024
Summary
A new electrode droplet microarray (eDMA) enables label-free, real-time monitoring of cellular responses to drugs. This miniaturized system is crucial for high-throughput drug development and personalized oncology using limited cell samples.
Area of Science:
- Biomedical Engineering
- Cellular Biology
- Toxicology
Background:
- Label-free impedance spectroscopy is vital for drug development and toxicology.
- Current methods lack miniaturization, hindering high-throughput screening of rare cells.
- Need for cost-effective, high-throughput screening with limited cell availability.
Purpose of the Study:
- To develop and validate a miniaturized bioelectrical signaling monitoring system (eDMA).
- To enable parallel, real-time, label-free detection of cellular responses in nanoliter droplets.
- To demonstrate the eDMA's utility in drug toxicity assessment and personalized oncology.
Main Methods:
- Fabrication and optimization of the electrode droplet microarray (eDMA) platform.
- Utilizing hydrophilic-superhydrophobic patterns to confine cells on microelectrodes.
- Employing impedance spectroscopy for real-time cellular response monitoring.
Main Results:
- Demonstrated real-time monitoring of anticancer drug cytotoxicity over 48 hours.
- Successfully calculated half-inhibitory concentration (IC50) values in real-time.
- Showcased parallel, dynamic assessment of drug responses in nanoliter droplets.
Conclusions:
- The eDMA platform facilitates miniaturized, high-throughput, label-free cellular analysis.
- eDMA is essential for personalized oncology and drug toxicity assessment with limited patient samples.
- The system enables dynamic, real-time evaluation of drug efficacy and toxicity.
